Stay updated with breaking news from Menarini Stemline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).
KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients...
This new post hoc analysis of the Phase 3 EMERALD trial evaluatedelacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations.This analysisshows a clinically meaningful
This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations. This analysis shows a clinically meaningful improvement in progression-free survival across the subgroups studied, including those patients with bone, liver and/or lung metastases, those with common […]
Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.